Literature DB >> 35937517

Two most common diagnoses among myriads of cystic lung diseases.

J Swol1, D Würflein1, J Böhm1, J H Ficker1.   

Abstract

BACKGROUND: Diffuse cystic lung diseases are a group of heterogeneous pathophysiological processes and include neoplastic, inflammatory, and infectious etiologies. This manuscript focuses on manifestations of pulmonary Langerhans cell histiocytosis (PLCH) and lymphangioleiomyomatosis (LAM). Description of the cases: Three female patients with LAM and one with PLCH are described. Stress dyspnea was a key symptom. There were similar cyst patterns in more than one lung lobe with a slow, progressive course. Histopathology confirmed the LAM diagnosis resulting from the nodular proliferate and the cyst wall that strongly expressed Human Melanoma Black-45 (HMB-45). A typical constellation for PLCH was demonstrated in high-resolution computed tomography (HRCT). It was found to be disseminated and relatively thick-walled cysts, mainly in the upper and middle parts. An individualized therapy was applied. Three patients with mild symptoms were followed up, including HRCT evaluations. Sirolimus was administered to one patient with a severe manifestation of LAM.
CONCLUSION: LAM and PLCH are rare. High-resolution computed tomography is an essential diagnostic tool. Lung emphysema as misdiagnosis should be avoided. The characteristics of pulmonary cysts, the cyst's wall regularity, and identification of associated pulmonary lesions, should be evaluated. A promising new therapy concept are mTOR inhibitors are, especially in LAM. The most important recommendation in PLCH is the cessation of cigarette smoking. HIPPOKRATIA 2021, 25 (2):83-86. Copyright 2021, Hippokratio General Hospital of Thessaloniki.

Entities:  

Keywords:  Pulmonary Langerhans cell histiocytosis; cystic lesion; diffuse cystic lung diseases; highresolution computed tomography; lymphangioleiomyomatosis; malignant histiocytosis; pulmonary cyst

Year:  2021        PMID: 35937517      PMCID: PMC9347339     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.522


  10 in total

Review 1.  Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis.

Authors:  Chalinee Monsereenusorn; Carlos Rodriguez-Galindo
Journal:  Hematol Oncol Clin North Am       Date:  2015-08-18       Impact factor: 3.722

Review 2.  Diffuse Cystic Lung Diseases.

Authors:  Baha Obaidat; Dina Yazdani; Kathryn A Wikenheiser-Brokamp; Nishant Gupta
Journal:  Respir Care       Date:  2019-10-15       Impact factor: 2.258

Review 3.  New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis.

Authors:  Olga Torre; Davide Elia; Antonella Caminati; Sergio Harari
Journal:  Eur Respir Rev       Date:  2017-09-27

Review 4.  Emerging biomarkers of lymphangioleiomyomatosis.

Authors:  Julie Nijmeh; Souheil El-Chemaly; Elizabeth P Henske
Journal:  Expert Rev Respir Med       Date:  2017-12-01       Impact factor: 3.772

5.  Treatment of lymphangioleiomyomatosis: building evidence in orphan diseases.

Authors:  Vincent Cottin
Journal:  Eur Respir J       Date:  2014-04       Impact factor: 16.671

6.  Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.

Authors:  Cherry Kim; Kyung-Hyun Do; Jaehyung Cha; Jin Woo Song; Sang Min Lee; Ki Yeol Lee
Journal:  Eur Radiol       Date:  2019-08-30       Impact factor: 5.315

Review 7.  Role of thoracic imaging in the management of lymphangioleiomyomatosis.

Authors:  Paola Crivelli; Roberta Eufrasia Ledda; Silvia Terraneo; Maurizio Conti; Gianluca Imeri; Elena Lesma; Fabiano Di Marco
Journal:  Respir Med       Date:  2019-08-22       Impact factor: 3.415

8.  Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Jianhua Yao; Mario Stylianou; Joel Moss
Journal:  Eur Respir J       Date:  2014-12-23       Impact factor: 16.671

9.  Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis.

Authors:  Muhammad Umair Khawar; Dina Yazdani; Zheng Zhu; Roman Jandarov; Daniel F Dilling; Nishant Gupta
Journal:  J Heart Lung Transplant       Date:  2019-06-21       Impact factor: 10.247

10.  The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.

Authors:  Qi Wang; Mengqi Luo; Bo Xiang; Siyuan Chen; Yi Ji
Journal:  Respir Res       Date:  2020-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.